[go: up one dir, main page]

WO2001012192A2 - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques Download PDF

Info

Publication number
WO2001012192A2
WO2001012192A2 PCT/GB2000/003116 GB0003116W WO0112192A2 WO 2001012192 A2 WO2001012192 A2 WO 2001012192A2 GB 0003116 W GB0003116 W GB 0003116W WO 0112192 A2 WO0112192 A2 WO 0112192A2
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
ethyl
propylsulphonyl
phenylethoxy
benzothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/003116
Other languages
English (en)
Other versions
WO2001012192A3 (fr
Inventor
Francis Ince
John Dixon
Philip Ronald Holt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Priority to AU64603/00A priority Critical patent/AU6460300A/en
Publication of WO2001012192A2 publication Critical patent/WO2001012192A2/fr
Publication of WO2001012192A3 publication Critical patent/WO2001012192A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline

Definitions

  • the present invention relates to combinations of pharmaceutically active substances for use in the treatment of obstructive airways diseases.
  • a pharmaceutical composition comprising, in admixture, a first active ingredient (A) being 4-hydroxy-7-[2- [2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]-l,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a second active ingredient (B) being either 5,5'-[(2- ⁇ ydroxy-l,3-propanediyl)bis(oxy)]bis[4-oxo-4 ⁇ -l-benzopyran-2-carboxylic acid, disodium salt (disodium cromoglycate) or 9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H- pyrano[3,2-g]quinoline-2,8-dicarboxylic acid (nedocromil).
  • the invention also provides a pharmaceutical product comprising, in combination, a preparation of a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]- propylsulphonyl]ethylamino]ethyl]-l,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a preparation of a second active ingredient (B) being either 5,5'-[(2- ⁇ ydroxy-l,3-propanediyl)bis(oxy)]bis[4-oxo-4 ⁇ -l-benzopyran-2-carboxylic acid, disodium salt (disodium cromoglycate) or 9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H- pyrano[3,2-g]quinoline-2,8-dicarboxylic acid (nedocromil) for sequential or separate use in therapy.
  • A a preparation of
  • the invention provides a kit comprising a preparation of a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]- ethylamino]ethyl]-l ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, a preparation of a second active ingredient (B) being either 5,5'-[(2- ⁇ ydroxy-l,3- propanediyl)bis(oxy)]bis[4-oxo-4H-l-benzopyran-2-carboxylic acid, disodium salt (disodium cromoglycate) or 9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2- g]quinoline-2,8-dicarboxylic acid (nedocromil), and instructions for the sequential or separate administration of the preparations to a patient in need thereof.
  • A
  • the combination of active ingredients according to the invention is advantageous because it is beneficial in the treatment of obstructive airways diseases including chronic obstructive pulmonary disease (COPD); and asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness).
  • COPD chronic obstructive pulmonary disease
  • asthma such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness).
  • the pharmaceutical composition of the invention may be prepared by mixing the first active ingredient (A) with the second active ingredient (B). Therefore, in another aspect of the present invention, there is provided a process for the preparation of a pharmaceutical composition which comprises mixing a first active ingredient (A) being 4-hydroxy-7-[2-[2- [3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, with a second active ingredient (B) being either 5,5'-[(2- ⁇ ydroxy-l,3-propanediyl)bis(oxy)]bis[4-oxo-4 ⁇ -l-benzopyran-2-carboxylic acid, disodium salt (disodium cromoglycate) or 9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H- pyrano[3,2-g]quinoline-2,
  • the pharmaceutical composition of the invention will typically comprise a total amount of first active ingredient (A) and second active ingredient (B) in the range from 0.05 to 99 %w (per cent by weight), more preferably in the range from 0.10 to 70 %w, and even more preferably in the range from 0.10 to 50 %w, all percentages by weight being based on total composition.
  • the first and second active ingredients (A) and (B) may alternatively be administered sequentially or separately in any suitable order to treat obstructive airways diseases.
  • sequential is meant that the first and second active ingredients are administered one immediately after the other. They still have the desired effect if they are administered separately but less than about 4 hours apart, preferably less than about 2 hours apart, more preferably less than about 30 minutes apart.
  • the active ingredients may, and indeed usually will, be used in admixture with one or more pharmaceutically acceptable ingredients which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity-regulating agents, surfactants, preservatives, flavourings and colorants.
  • pharmaceutically acceptable ingredients which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity-regulating agents, surfactants, preservatives, flavourings and colorants.
  • the dosages administered will, of course, vary with the first and second active ingredients (A) and (B) employed, the mode of administration, the treatment desired and the disorder indicated. If the active ingredients are administered by inhalation, then the total daily dosage of first active ingredient (A) and second active ingredient (B) together is preferably in the range from 5 to 1500 ⁇ g, e.g. from 10 to 1450 ⁇ g or from 20 to 1400 ⁇ g.
  • the pharmaceutical composition, pharmaceutical product or kit according to the invention may be administered as divided doses from 1 to 4 times a day, and preferably once or twice a day.
  • the first and second active ingredients (A) and (B) may be administered topically (to the lung and/or airways) in the form of solutions, suspensions, aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions.
  • metered dose inhaler devices may be used to administer the active ingredient(s), dispersed in a suitable propellant and with or without additional excipients such as ethanol, surfactants, lubricants or stabilising agents.
  • suitable propellants include hydrocarbon, chlorofluorocarbon and hydrofluoroalkane (e.g. heptafluoroalkane) propellants, or mixtures of any such propellants.
  • Especially preferred propellants are HFA-134a and HFA-227, each of which may be used alone or in combination with other propellants and/or surfactants and/or other excipients.
  • Nebulised aqueous suspensions or, preferably, solutions may also be employed, with or without a suitable pH and/or tonicity adjustment, either as a unit-dose or multi-dose formulations.
  • Dry powder inhalers may be used to administer the active ingredient(s), alone or in combination with a pharmaceutically-acceptable carrier, in the latter case either as a finely divided powder or as an ordered mixture.
  • the dry powder inhaler may be single dose or multi-dose and may utilise a dry powder or a powder-containing capsule.
  • Metered dose inhaler, nebuliser and dry powder inhaler devices are well known and a variety of such devices are available.
  • Tablets and gelatin capsules, which may be coated if desired, containing the active ingredient(s) may, for example, also include one or more diluents, carriers, binders, lubricants or stabilising agents.
  • Injectable solutions of the active ingredient(s) may also contain, for example, one or more preservatives, stabilising agents, viscosity-regulating agents, emulsifying agents or buffering agents.
  • the present invention further provides the use of a pharmaceutical composition, pharmaceutical product or kit according to the invention in the manufacture of a medicament for the treatment of an obstructive airways disease. Also, the present invention provides a method of treating, or reducing the risk of, an obstructive airways disease in a patient suffering from, or at risk of, the disease, which comprises administering to the patient a therapeutically effective amount of a pharmaceutical composition of the invention.
  • the present invention provides a method of treating, or reducing the risk of, an obstructive airways disease which comprises sequentially or separately administering (in any suitable order) to a patient suffering from, or at risk of, the disease
  • a (therapeutically effective) dose of a second active ingredient (B) being either 5,5'-[(2- ⁇ ydroxy-l,3-propanediyl)bis(oxy)]bis[4-oxo-4 ⁇ -l-benzopyran-2-carboxylic acid, disodium salt (disodium cromoglycate) or 9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H- pyrano[3,2-g]quinoline-2,8-dicarboxylic acid (nedocromil).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique, un produit ou un kit pharmaceutique comprenant un premier composant actif (A), qui se présente comme 4-hydroxy-7[2-[2-[3-[2-phényléthoxy]propylsulphonyl]éthylamino]éthyl]-1,3-benzothiazol-2(3H)-one ou un sel pharmaceutiquement acceptable de celui-ci et un deuxième composant actif (B), qui se présente comme nedocromile, la composition étant utilisée pour traiter des maladies obstructives des voies d'air.
PCT/GB2000/003116 1999-08-18 2000-08-14 Compositions pharmaceutiques Ceased WO2001012192A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64603/00A AU6460300A (en) 1999-08-18 2000-08-14 Pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902938-1 1999-08-18
SE9902938A SE9902938D0 (sv) 1999-08-18 1999-08-18 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
WO2001012192A2 true WO2001012192A2 (fr) 2001-02-22
WO2001012192A3 WO2001012192A3 (fr) 2001-12-13

Family

ID=20416696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003116 Ceased WO2001012192A2 (fr) 1999-08-18 2000-08-14 Compositions pharmaceutiques

Country Status (3)

Country Link
AU (1) AU6460300A (fr)
SE (1) SE9902938D0 (fr)
WO (1) WO2001012192A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7700782B2 (en) 2006-12-20 2010-04-20 Astrazeneca Ab Compounds 569
US7709511B2 (en) 2005-08-09 2010-05-04 Astrazeneca Ab Benzothiazolone derivatives
US7951954B2 (en) 2006-03-14 2011-05-31 Astrazeneca Ab Bezothiazol derivatives as Beta2 adrenoreceptor agonists
US8017602B2 (en) 2008-06-18 2011-09-13 Astrazeneca Ab N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
US8058294B2 (en) 2007-02-08 2011-11-15 Astrazeneca Ab Pharmaceutical salts of N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-napthyl)ethoxy]propanamide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211172D0 (en) * 1992-05-27 1992-07-08 Fisons Plc Compounds

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7838535B2 (en) 2003-11-21 2010-11-23 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7842704B2 (en) 2003-11-21 2010-11-30 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US8247564B2 (en) 2003-11-21 2012-08-21 Theravance, Inc. Compounds having BETA2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7709511B2 (en) 2005-08-09 2010-05-04 Astrazeneca Ab Benzothiazolone derivatives
US7951954B2 (en) 2006-03-14 2011-05-31 Astrazeneca Ab Bezothiazol derivatives as Beta2 adrenoreceptor agonists
US7700782B2 (en) 2006-12-20 2010-04-20 Astrazeneca Ab Compounds 569
US8058294B2 (en) 2007-02-08 2011-11-15 Astrazeneca Ab Pharmaceutical salts of N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-napthyl)ethoxy]propanamide
US8017602B2 (en) 2008-06-18 2011-09-13 Astrazeneca Ab N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy

Also Published As

Publication number Publication date
WO2001012192A3 (fr) 2001-12-13
SE9902938D0 (sv) 1999-08-18
AU6460300A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
JPH03167120A (ja) 呼吸疾患治療薬
JP2002536408A (ja) フォルモテロールとチオトロピウム塩の組合わせ
CA2239308A1 (fr) Nouvelle combinaison
RU2001123923A (ru) Композиции, включающие формотерол и соль тиотропия
EA008828B1 (ru) Лекарство, содержащее сильнодействующий бета2-агонист длительного действия в комбинации с другими активными ингредиентами
EP1272162A1 (fr) Formulations sous forme de poudre seche stabilisees
US20080020048A1 (en) Treatment of Respiratory Disease
KR20070042917A (ko) 소아 천식의 치료
WO2001012167A2 (fr) Compositions pharmaceutiques
AU1321401A (en) New combination comprising a beta 2 (beta)2 adreno receptor agonist and a leukotriene receptor antagonist
ZA200301475B (en) Pharmaceutical formulation of salmeterol and fluticasone propionate.
WO2002028368A1 (fr) Nouveau medicament combine pour le traitement de l"asthme
WO2001012192A2 (fr) Compositions pharmaceutiques
EA009935B1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол
CA2389111C (fr) Nouvelle association de loteprednol et d'agonistes de l'adrenocepteur .beta.2
JP7309791B2 (ja) イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用
EP1359902B1 (fr) Composition bimodale de poudre seche pour l'inhalation
EP0640338A1 (fr) Le cromoglycate de sodium dans le traitement des infections des voies respinatoires supérieures
JP2021176903A5 (fr)
US20060199865A1 (en) Synergistic combination comprising roflumilast and (r,r) - formoterol
AU6133186A (en) Use of gallopamil for treating bronchospastic airway diseases
WO1987000047A1 (fr) Procede et composition de traitement d'affections pulmonaires obstructives chroniques
JPWO2017177966A5 (fr)
HK1081862B (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
HK1081861B (en) New synergistic combination comprising roflumilast and formoterol

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09674083

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP